Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.
The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 26 | 0.00 Increased by +100.00% | - |
| Dec 2, 25 | 0.00 Decreased by N/A% | - |
| Sep 5, 25 | -2.29 Increased by +98.86% | - |
| Apr 10, 25 | -4.02 Decreased by -1.91 K% | - |
| Mar 31, 25 | -4.02 Decreased by -1.91 K% | - |
| Nov 29, 24 | 0.00 Decreased by N/A% | - |
| Aug 29, 24 | -200.00 Decreased by -78.50 K% | -30.00 Decreased by -566.67% |
| Apr 8, 24 | -0.20 Increased by +87.47% | -0.03 Decreased by -566.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 2.04 M Increased by +58.59% | -2.07 M Decreased by -33.84% | Decreased by -101.32% Increased by +15.61% |
| Mar 31, 25 | 2.04 M Increased by +259.38% | -2.07 M Increased by +84.74% | Decreased by -101.32% Increased by +95.75% |
| Sep 30, 24 | 2.74 M Increased by +52.31% | -2.59 M Decreased by -440.34% | Decreased by -94.68% Decreased by -323.45% |
| Jun 30, 24 | 1.29 M Decreased by -89.95% | -1.54 M Increased by +58.59% | Decreased by -120.06% Decreased by -312.06% |
| Mar 31, 24 | 1.29 M Decreased by -89.95% | -1.54 M Decreased by -162.01% | Decreased by -120.06% Decreased by -717.09% |
| Sep 30, 23 | 567.50 K Decreased by -96.77% | -13.54 M Increased by +62.07% | Decreased by -2.39 K% Decreased by -1.07 K% |
| Jun 30, 23 | 1.80 M Decreased by -90.21% | 761.00 K Increased by +105.34% | Increased by +42.37% Increased by +154.50% |
| Mar 31, 23 | 12.80 M Decreased by -2.34% | -3.73 M Increased by +81.83% | Decreased by -29.14% Increased by +81.40% |